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INTRODUCTION
In Korea, as in western countries, the current number of
people with obesity is the highest ever recorded (1). As a result,
the escalating health risks due to obesity are not only a great
problem in the western world, but also in the Korean society
(1). Many studies have demonstrated that obesity is a strong
risk factor for fatty liver (2, 3). However, the use of the term
obesity is too broad. While overall obesity is clearly associated
with fatty liver, body fat distribution appears to play a more
important role in the pathogenesis of fatty liver. In particular,
central obesity may be a key determinant in the pathogenesis
of fatty liver, via both a strong association with insulin resis-
tance and possibly as a source of free fatty acids (4) and has
also been positively correlated with liver fat (5, 6) and hepat-
ic insulin resistance in both men and women (7). Further-
more, in central obesity, especially accumulation of visceral
fat is a more important risk factor for metabolic syndrome
than subcutaneous fat, owing to its steatogenesis and the
production of various cytokines (8, 9). Other studies have
indicated that serum triglycerides, free fatty acid, leptin,
and tumor necrosis factor (TNF)- from adipocytes in the
visceral fat participate in the development of metabolic syn-
drome, including insulin resistance (10, 11). However, few
studies have suggested a relationship between fatty liver and
severity of visceral fat accumulation, especially in type 2 dia-
betic patients in Asia. From these results, we can conclude
that accumulation of visceral fat may play a significant role
in the severity of fatty liver disease. The aim of the present
study was, therefore, to evaluate whether visceral adiposity




From January 2003 to June 2006, 4,793 patients were eval-
uated for type 2 diabetes at the Huh clinic. The exclusion cri-
teria were as the follows: 1) alcohol intake of 140 g/week or
more, 2) a positive serologic finding for hepatitis B or C virus,
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Visceral Fat Thickness Predicts Fatty Liver in Koreans with
Type 2 Diabetes Mellitus
Our aim was to study whether visceral adiposity is a predictor of diabetic fatty liver
in Korean type 2 diabetes mellitus. In this study, abdominal ultrasonography was
used to assess the presence of fatty liver in 1,898 patients with type 2 diabetes.
We measured visceral fat thickness by high-resolutional ultrasonography and insulin
resistance by Kitt. Half of the cohort had a fatty liver (50.2%). High visceral fat thick-
ness had the highest odds ratio for developing fatty liver in both sexes (odds ratio
[S.D]: 3.14 [2.24-4.69], p<0.00 in male, 2.84 [2.04-3.93], p<0.00 in female). In addi-
tion, visceral fat thickness of 42.45 and 37.7 mm in men and women, respectively,
were chosen as the discriminating value to predict the presence of fatty liver with a
sensitivity of 71% and 73% and a specificity of 70% and 70% in men and women,
respectively. The area under the receiver-operating characteristics curve was
0.759 in men and 0.764 in women. Therefore we could conclude that the degree
of visceral adiposity predicts the presence of fatty liver type 2 diabetes mellitus,
whether centrally obese or not, suggesting that hepatic fat accumulation in a dia-
betic fatty liver may be influenced by visceral fat accumulation regardless of waist
circumference.
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3) the presence of auto-antibodies indicative of autoimmune
hepatitis, 4) a history of another known liver disease, 5) malig-
nancy, and 6) a medication history of insulin, corticosteroids,
estrogens, methotrexate, tetracycline hydrochloride, amio-
darone or tamoxifen citrate, or antiobesity drugs in the pre-
vious 6 months.
Finally, 1,898 patients with type 2 diabetes mellitus were
enrolled in the study. The study protocol was approved by the
Yonsei Medical University College of Medicine ethnical com-
mittee, and informed consent was obtained from each par-
ticipant. All participants were interviewed to obtain their
history of hypertension, myocardial infarction, cerebrovas-
cular accident, and previous medication including insulin
and alcohol consumption. The differentiation of each oral
hypoglycemic agents was not carried out and the levels of
diet and physical activity were not evaluated in this study.
Their height, weight, waist and hip ratio, waist circumfer-
ence were measured to the nearest half-centimeter or half-
kilogram. The waist circumference was measured at the mid-
point between the lower border of the rib cage and the iliac
crest and the hip circumference at the maximal protrusion
of the greater trochanter. 
The laboratory evaluation included the fasting blood glu-
cose, fasting serum insulin, fasting c-peptide, HbA1c, total
cholesterol, high-density lipoprotein cholesterol (HDL-C),
triglyceride (TG), and, aspartate aminotransferase (AST), and
alanine aminotransferase (ALT). The low-density lipoprotein
cholesterol (LDL-C) was calculated using the equation by
Friedewald et al. (12). The short insulin tolerance test was
performed between 8 AM and 9 AM after an overnight fast.
The patients were instructed not to take their morning insulin.
An arterialized superficial hand vein was used for blood sam-
pling and for insulin injection. The patients rested in the
supine position for at least 30 min before the test. The test
was then started with an intravenous bolus dose (0.1 U/kg)
of ultra-rapid human insulin. Blood samples for blood glu-
cose determination were taken before and then 6 and 15 min
after administration of the insulin, with close observation of
hypoglycemic events. Linear regression was used to estimate
the slope of decline in log transformed blood glucose con-
centration. Blood glucose values from 4 to 16 min were used
for the analysis. Kitt was calculated from the formula 69.3/t1/2
(13, 14). The blood pressure was measured using a standard
mercury sphygmomanometer after the subject had been seat-
ed for at least 10 min. The percentage of whole blood fat was
measured by means of the bioelectrical impedance analysis
method (Inbody 2.0, Biospace Co. Ltd. Seoul, Korea). The
diagnosis of fatty liver was based on the results of abdomi-
nal ultrasonography which was done by a well trained tech-
nician. All ultrasonographic images were stored in the image
server. One gastroenterologist reviewed the images and made
the diagnosis of fatty liver without reference to any of the
participants’ other individual data for the 4 known criteria
(hepato-renal echo contrast, liver brightness, deep attenua-
tion, and vascular blurring). The participants were required
to have a diagnosis of nonalcoholic fatty liver. Another ultra-
sonography was performed to measure visceral fat thickness
using a high-resolution ultrasonographic system (SA 9900;
Medison, Seoul, Korea) as described by Suzuki et al., Armelli-
ni et al., and Kim et al. (15-17). The subjects were examined
in the supine position and all frozen images were collected
immediately after inspiration to avoid the effect of respira-
tion. Visceral fat thickness was defined as the distance between
the anterior wall of the aorta and the internal face of the rec-
toabdominal muscle perpendicular to the aorta. Transverse
scanning was performed by using a 3.5 MHz probe to mea-
sure visceral fat thickness at 1 cm above the umbilicus.
Definition of metabolic variables
To define risk factors for fatty liver in both sexes, we deter-
mined the odds ratio of developing fatty liver in type 2 dia-
betic patients with high visceral fat thickness, hypertriglyc-
eridemia, low HDL-C, obesity, central obesity, insulin resis-
tance, and fasting hyperglycemia compared to patients with-
out these conditions. Men and women with waist circum-
ference values of 90 and 80 cm or more, respectively, were
considered to have central obesity and obesity was defined
as a BMI of 25 kg/m2 or more, according to the World Health
Organization perspective on the western pacific region for
Asians (18). The presence of insulin resistance was defined
as a kitt of 2.5%/min or less. Hypertriglyceridemia and low
HDL-C level were defined according to the Adult treatment
Panel III of the National Cholesterol Education Program
guidelines (Triglyceride level >1.7 mM/L HDL-C level <1.0
mM/L in men or 1.3 mM/L in women) (19). A high visceral
fat thickness was defined according to Kim et al. (VFT >47.6
mm in men or >35.5 mm in women) (17).
Statistical analysis
Statistical analyses were performed using SPSS software
(Version 11.5; SPSS Inc, Chicago, IL, U.S.A.) and were car-
ried out separately in men and women because of the differ-
ence in basal clinical characteristics between two sexes. The
intergoup comparisons were performed using an independent
t-test. Logistic regression, which had been adjusted for age,
was used to evaluate risk factors of fatty liver in male and
female type 2 diabetes mellitus patients. To assess the cutoff
point of visceral fat thickness for fatty liver, a receiver-operat-
ing characteristics (ROC) curve was performed to determine
the sensitivity and specificity using visceral fat thickness as
a predictor of fatty liver. A p<0.05 was considered significant.
RESULTS
The prevalence of fatty liver was 50.2% in all the subjects
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and slightly higher in males. The characteristics of the subjects
according to sex are shown in Table 1. In males, there were
significant differences between the subjects with and without
fatty liver in terms of age, weight, BMI, waist circumference,
waist hip ratio, percentage of body fat, blood pressure, serum
insulin, c-peptide, Kitt, total cholesterol, HDL-C, triglyc-
eride, AST, ALT, and visceral fat thickness. In females, a com-
parison between subjects with and without fatty liver showed
a tendency similar to that in the male group except that serum
insulin showed no difference and HbA1c and LDL-C were
higher in fatty liver subjects (Table 1). According to multi-
ple logistic regression analysis, high visceral fat thickness,
hypertriglyceridemia, central obesity, insulin resistance, and
low HDL-C were independently associated with fatty liver
in male type 2 diabetes patients, whereas in female patients,
high visceral fat thickness, central obesity, insulin resistance,
and hypertriglyceridemia were associated with fatty liver
(Table 2). The odds ratio of high visceral fat thickness for
fatty liver showed the highest values as 3.14 (CI: 2.24-4.39)
and 2.84 (CI: 2.04-3.93) in males and females, respectively
(Table 2).
As shown in Fig. 1, the area under the ROC curve for VFT
as a predictor of the presence of fatty liver was 0.759 (95%
CI: 0.734-0.794; p<0.001) in the men and 0.764 (95% CI:
Data are expressed as mean±SD.
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density liporotein cholesterol.
Non fatty liver Fatty liver
p
Non fatty liver Fatty liver
p
(n=452) (n=492) (n=493) (n=461)
N=1,898
Male (n=944) Female (n=954)
Age (yr) 55.4±11.2 53.7±10.6 0.01 56.8±10.2 58.3±9.3 0.02
Height (cm) 168.7±5.8 169.4±6.1 0.06 155.9±5.4 156.3±5.5 0.26
Weight (kg) 65.2±11.1 73.8±13.7 0.00 54.9±8.7 63.3±10.4 0.00
BMI (kg/m2) 22.8±4.4 25.6±4.6 0.00 22.7±3.6 25.6±4.3 0.00
Waist circumference (cm) 80.6±12.4 88.4±11.9 0.00 75.0±10.8 83.9±8.5 0.00
Visceral fat thickness (mm) 39.9±15.8 56.18±17.2 0.00 33.3±17.2 48.3±16.7 0.00
% of body fat (%) 20.6±5.4 24.9±5.4 0.00 28.7±5.8 33.4±6.1 0.00
Systolic blood pressure (mmHg) 132.8±20.7 135.7±17.5 0.01 134.9±20.7 142.0±18.9 0.00
Diastolic blood pressure (mmHg) 87.1±12.8 90.6±11.2 0.00 84.5±10.9 88.3±10.1 0.00
S-insulin (pM/L) 55.9±1.06 89.6±274.8 0.01 89.6±276.2 124.1±445.6 0.15
C-peptide ( g/L) 1.7±1.0 2.3±0.9 0.00 1.5±0.8 2.2±1.0 0.00
Fasting blood glucose (mM/L) 7.51±3.49 7.48±2.72 0.87 7.44±3.4 7.46±2.62 0.91
HbA1c (%) 8.1±2.4 8.2±1.8 0.43 8.0±2.0 8.3±1.7 0.03
Kitt (%/min) 2.2±1.0 1.8±0.9 0.00 2.2±0.9 1.7±0.8 0.00
Total cholesterol (mM/L) 4.65±1.14 4.97±1.10 0.00 4.99±1.16 5.26±1.1 0.00
HDL-C (mM/L) 1.31±0.39 1.16±0.31 0.00 1.32±0.46 1.33±0.35 0.00
Triglyceride (mM/L) 1.4±1.17 2.13±1.58 0.00 1.39±0.75 1.91±1.02 0.00
LDL-C (mM/L) 2.68±0.89 2.74±1.04 0.30 2.84±0.93 3.01±1.00 0.00
AST (ukat/L) 0.43±0.17 0.55±0.33 0.00 0.43±0.18 0.55±0.31 0.00
ALT (ukat/L) 0.41±0.22 0.62±0.47 0.00 0.38±0.25 0.52±0.30 0.00
Table 1. Patient characteristics according to sex 
Data are expressed as odds ratios (95% confidence intervals). Significant values appear in bold type. * p<0.05.
VFT, visceral fat thick; HDL-C, high-density lipoprotein cholesterol. 
Male group Female group
Disorder
OR (95%CI) p OR (95%CI) p
High VFT 3.14 (2.24-4.39)* 0.00 2.84 (2.04-3.93)* 0.00
Hypertriglyceridemia 2.40 (1.73-3.32)* 0.00 1.71 (1.22-2.40)* 0.00
Low HDL-C level 1.48 (1.05-3.29)* 0.02 1.05 (0.76-1.47) 0.75
Obesity 1.64 (1.13-2.38)* 0.01 2.16 (1.47-3.18)* 0.00
Central obesity 1.96 (1.28-2.98)* 0.00 2.23 (1.51-3.29)* 0.00
Insulin resistance 1.60 (1.13-2.26)* 0.00 1.73 (1.21-2.50)* 0.00
Fasting hyperglycemia 1.18 (0.76-1.84) 0.47 0.96 (0.625-1.48) 0.86
High HbA1c 1.03 (0.71-1.49) 0.86 1.45 (0.99-2.13) 0.06
Age 0.98 (0.97-1.19) 0.12 0.99 (0.98-1.01) 0.79
Table 2. Odds ratio of the fatty liver in type 2 diabetes male and female subjects
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0.728-0.789) in the women. A VFT of 42.45 mm and 37.7
mm in men and women, respectively, was found to be the
discriminating cutoff point for fatty liver with sensitivity of
71% and 73% and a specificity of 70% and 70% in men
and women, respectively.
DISCUSSION
This study shows a high prevalence of fatty liver in Korean
type 2 diabetes patients, and this is the first large study to show
the important role of visceral fat thickness for the development
of fatty liver in Korean type 2 diabetes patients. Also, this is
the first large study to determine the cutoff point of visceral
fat thickness for fatty liver in type 2 diabetes patients.
The prevalence of fatty liver varies from 10 to 20% in the
general population (20) and increases to 50-75% in subjects
with type 2 diabetes mellitus (21). We have estimated that
approximately 50.2% of patients had a fatty liver in our study.
This result is similar to the findings from other studies (22, 23).
Our study confirmed the previous finding that Asian patients
with fatty liver have metabolic disorders that are similar to
those of their western counterparts (24). Patients with fatty
liver showed a higher prevalence of metabolic components such
as obesity, hypertension, and dyslipidemia with a high rate of
insulin resistance in our study. South Asian people includ-
ing South Koreans are reported to be more centrally obese
for the same degree of weight gain when compared to East
Asian people, but the former are more insulin resistant (25).
This is also true for cases of non-alcoholic steatohepatitis
(NASH) in seemingly lean (but actually centrally obese) South
Asians. Among Pacific Islanders, the converse appears to hold
true; when compared to Caucasians, insulin resistance is lower
for any given body mass index. These data refer to the gen-
eral population, but since our data were derived mainly from
type 2 diabetes patients, the results are somewhat different.
Compared to cases of fatty liver in the general population
from South Asia, fatty liver patients with type 2 diabetes
mellitus had a higher rate of obesity, insulin resistance, and
a central obesity of 44.9% and 68.1% in females and males,
respectively. This suggests that South Asians with type 2
diabetes mellitus do not follow the general rule of being lean
but centrally obese (26); however, they do show characteris-
tics similar to those of western people with a fatty liver.
According to previous studies on Asian people, fatty liver
is more prominent in men (24, 26, 27). However, in our study,
the male-to-female ratio was almost equivalent. This might
also represent the difference between the prevalence of fatty
liver in the general population and that in type 2 diabetes mel-
litus patients. Conclusively, when South Asian patients have
a fatty liver and type 2 diabetes mellitus, they show the same
trends as western people.
Patients with a fatty liver showed an increased visceral fat
thickness over those without fatty liver, independently of waist
circumference. In contrast to male patients with a fatty liver
who were not centrally obese, female patients with a fatty liver
had an increased waist circumference, exceeding 80 cm, the
range for central obesity. This means that regardless of waist
circumference, fatty liver patients always have visceral fat thick-
ness. The different result in male and female group might be
Fig. 1. Receiver-operating characteristic (ROC) analysis of visceral fat thickness as a predictor of the presence of fatty liver in men (A)
and women (B). Visceral fat thickness of 42.4 and 37.7 mm in men and women, respectively, were chosen as the discriminating value to
predict the presence of fatty liver with a sensitivity of 71% and 73% and a specificity of 70% and 70% in men and women, respectively.
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due to the different actions of the sex hormones such as testos-
terone and estrogen. It appears that the effects of sex steroids
on visceral fat deposition vary in men and women, perhaps
owing to the effects of progestins (28). The biochemical or
molecular basis for the regional differences in sex steroid effects
on adipose metabolism is not well elucidated. However, estro-
gen appears to produce a greater stimulation of preadipocyte
proliferation in subcutaneous than in omental fat (29, 30), but
testosterone decreases subcutaneous fat and increases visceral
fat (28, 31). This suggests that no matter whether patients are
centrally obese or not, they might have a high amount of
visceral fat, and this can be a major risk factor for fatty liver
in male type 2 diabetes patients. 
In terms of lipid profiles, the presence of fatty livers was asso-
ciated with elevated total cholesterol, triglyceride, and reduced
serum HDL-C in both sexes, but there was no consistent cor-
relation with LDL-C levels in either sex. This might be ex-
plained by diabetic dyslipidemia and its role in atherogenesis,
which would affect the LDL particle size rather than the
LDL-C level. Levels of fasting blood glucose and HbA1c were
increased in patients with fatty liver but not significantly. In
type 1 diabetes, hepatic steatosis is related to inadequate serum
levels of insulin and hence to poor diabetic control. In type
2 diabetes, however, it is primarily related to concurrent
obesity rather than the duration of diabetes or the adequacy
of control (21). Our study was mainly conducted in type 2
diabetes patients, and this is why our data showed no sig-
nificant difference in FBG and HbA1c levels between the
patients with and without fatty liver. Patients with hepatic
steatosis usually have elevated transaminase levels (32), and
our data were consistent with this finding. This can explain
the elevated c-peptide and s-insulin levels in both male and
female patients with fatty liver.
The relationship between obesity and fatty liver is well
known (2, 3). However, it has been proposed that the waist
circumference, which reflects central obesity, is more related
to fatty liver than BMI is (33, 34). In multiple regression anal-
ysis, adjusted for age, insulin resistance, and dyslipidemia, the
visceral fat thickness of all metabolic indices showed the stro-
ngest predictive value for fatty liver (OR, 3.14 [CI: 2.24-4.39]
and 2.84 [CI: 2.24-4.39] in males and females, respectively).
This study indicates that fatty liver is implicated, in centrally
non-obese male subjects with a waist circumference <90 cm
but with high visceral fat accumulation. Previous studies on
the relationship between visceral fat accumulation and fatty
liver exist, but only a few included type 2 diabetes patients
(22, 35).
In addition, this study suggested that a VFT of 42.5 mm
and 37.7 mm in men and women, respectively, was a cutoff
for predicting the presence of fatty liver with a high speci-
ficity and sensitivity in patients with type 2 diabetes melli-
tus. Therefore, the ultrasonographic measurement of VFT
might be a good and noninvasive method for predicting the
presence of fatty liver in type 2 diabetes patients.
Our study was limited by the fact that ultrasonography can-
not distinguish simple fatty liver from steatohepatitis, which
can only be detected by a liver biopsy. Further studies are
required to assess the relationship between the pathological
evaluation for the grading of a fatty liver and steatoheaptitis
and visceral fat accumulation. In addition, ultrasonography
is not a method normally used to quantify the amount of
fat, but may be used as an alternative method of assessing
visceral adiposity. According to Kim et al. (17), the intraob-
servational reproducibility of the ultrasonographic estima-
tion was 1.5-2.0% for the visceral fat thickness and the repro-
ducibility between the 2 operators was 1.8-2.8%. So we
should keep in mind that ultrasonography has such limita-
tions in measuring visceral fat thickness. 
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